NRG1 and melanoma: In summary we believe that at least in melanoma, when cells are exposed to targeted therapy, redundant cell autonomous and non- cell autonomous mechanisms are activated leading to the production of NRG1 by both melanoma cells and cells of the tumour microenvironment which converge into the activation of the ErbB3/PI3K/AKT pathway.